TSE:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis C$2.70 -0.03 (-1.10%) (As of 04:13 PM ET) Add Compare Share Share Today's RangeC$2.60▼C$2.7850-Day RangeC$2.40▼C$4.0752-Week RangeC$0.91▼C$4.26Volume124,557 shsAverage Volume157,590 shsMarket CapitalizationC$186.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlines Get Cardiol Therapeutics alerts: Email Address Ad Stansberry Research25th AmendmentIt's not surprising that talk of invoking the 25th Amendment (to remove Biden from office) has surfaced.But what happens next? About Cardiol Therapeutics Stock (TSE:CRDL)Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Read More CRDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRDL Stock News HeadlinesJune 25, 2024 | insidertrades.comDavid Elsley Acquires 50,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) StockJune 26, 2024 | americanbankingnews.comCardiol Therapeutics (TSE:CRDL) Trading Up 10.4% Following Insider Buying ActivityJuly 2, 2024 | Behind the Markets (Ad)[Breaking] Classified Wargames Reveal Grave Threat from ChinaThe economic fallout could be devastating for unprepared investors. But sectors like aerospace & defense may see soaring demand. Don't be caught off guard - get the details on the weapons makers set to boom if war breaks out.May 14, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cardiol Therapeutics (CRDL) and MicroPort Scientific (OtherMCRPF)May 10, 2024 | baystreet.caManufacturing, Housing Due Next Week in CanadaApril 23, 2024 | markets.businessinsider.comBuy Rating on Cardiol Therapeutics: Projected Blockbuster CardiolRx’s Strategic Advantages and Market PotentialApril 20, 2024 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT up on Tuesday (CRDL-WT-A)April 13, 2024 | seekingalpha.comCRDL:CA Cardiol Therapeutics Inc.July 2, 2024 | Behind the Markets (Ad)[Breaking] Classified Wargames Reveal Grave Threat from ChinaThe economic fallout could be devastating for unprepared investors. But sectors like aerospace & defense may see soaring demand. Don't be caught off guard - get the details on the weapons makers set to boom if war breaks out.February 21, 2024 | finance.yahoo.comCardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent PericarditisFebruary 9, 2024 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Monday (CRDL-WT-A)February 2, 2024 | finance.yahoo.comIs Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?January 30, 2024 | morningstar.comCardiol Therapeutics Inc Class ADecember 5, 2023 | finance.yahoo.comCardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-PilotNovember 1, 2023 | proactiveinvestors.comCardiol Therapeutics reaches new milestone in Phase II study for recurrent pericarditisNovember 1, 2023 | finance.yahoo.comCardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent PericarditisOctober 23, 2023 | finanznachrichten.deCardiol Therapeutics Inc.: Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementOctober 13, 2023 | finance.yahoo.comCardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart DiseasesOctober 13, 2023 | finance.yahoo.comCardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart DiseasesOctober 11, 2023 | proactiveinvestors.comCardiol Therapeutics releases positive study results of...Cardiol Therapeutics releases positive study results of...October 10, 2023 | benzinga.comCBD To Treat Heart Failure? New Study Shows Its Cardioprotective EffectsSeptember 28, 2023 | finanznachrichten.deCardiol Therapeutics Inc.: Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare ConferenceSeptember 26, 2023 | finance.yahoo.comCardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare ConferenceSeptember 19, 2023 | proactiveinvestors.comCardiol Therapeutics on track to complete enrollment for acute myocarditis trial six months ahead of scheduleAugust 16, 2023 | msn.comCardiol Therapeutics Inc. (CRDL) Upgraded to Buy: Here's What You Should KnowJune 6, 2023 | finance.yahoo.comCRDL.TO - Cardiol Therapeutics Inc.May 19, 2023 | investing.comCardiol Therapeutics (CRDL) Earnings Dates & ReportsSee More Headlines Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CRDL CUSIPN/A CIKN/A Webwww.cardiolrx.com Phone289 910 0850FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-30,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-92.11% Return on Assets-45.35% Debt Debt-to-Equity Ratio0.83 Current Ratio2.81 Quick Ratio6.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$2.78 per share Price / Cash Flow0.98 Book ValueC$0.30 per share Price / Book9.10Miscellaneous Outstanding Shares69,000,000Free FloatN/AMarket CapC$188.37 million OptionableNot Optionable Beta0.68 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. David G. Elsley MBAPresident, CEO & DirectorMr. Christopher J. Waddick C.A.C.M.A., CPA, CMA, MBA, CFO, Corporate Secretary & DirectorMr. Bernard Lim B.Sc.Chief Operating OfficerDr. Andrew Warwick Hamer M.D. (Age 62)Chief Medical Officer & Head of Research & Development Comp: $746.56kTrevor BurnsInvestor RelationsKey CompetitorsCanopy GrowthTSE:WEEDKnight TherapeuticsTSE:GUDAurora CannabisTSE:ACBSupreme CannabisTSE:FIREESSA PharmaCVE:EPIView All CompetitorsInsidersDavid ElsleyBought 50,000 shares on 6/24/2024Total: C$138,490.00 ($2.77/share) CRDL Stock Analysis - Frequently Asked Questions Should I buy or sell Cardiol Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRDL shares. View CRDL analyst ratings or view top-rated stocks. How have CRDL shares performed in 2024? Cardiol Therapeutics' stock was trading at C$1.10 at the beginning of the year. Since then, CRDL stock has increased by 145.5% and is now trading at C$2.70. View the best growth stocks for 2024 here. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:CRDL) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | SponsoredThe Only Retirement Stock You'll Ever Need? Discover NowThere is a little region of America called Loudoun County. The value of each square mile has shot up close ...Behind the Markets | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden’s inner circle turns against him?On August 19, the Democratic party will take the stage in Chicago and officially nominate their presidential c...Paradigm Press | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDL Stock Alerts